Abdera to Detail Cancer Drug Pipeline at JP Morgan Conference

Abdera to Showcase Phase 1 Cancer Drug on January 13

Abdera Therapeutics will present its pipeline of precision cancer-fighting drugs at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, at 10:00 a.m. PT. President and CEO Lori Lyons-Williams is scheduled to provide an overview of the company’s clinical-stage radiotherapeutics. The presentation will feature ABD-147, a therapy targeting the delta-like ligand 3 (DLL3) protein.

ABD-147 is currently being evaluated in a Phase 1 clinical trial for treating small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC). The drug is designed to deliver Actinium-225, a potent radioisotope, to selectively destroy solid tumors.

ROVEr Platform Fuels 2026 Clinical Development Plans

Abdera’s drug development is powered by its proprietary Radio Optimized Vector Engineering (ROVEr™) platform, which engineers antibodies to deliver targeted radiopharmaceuticals. Building on this technology, the company is also advancing ABD-320, a therapy targeting the 5T4 protein, which holds pan-cancer potential.

The company confirmed that ABD-320 is on track to enter clinical development in 2026. This signals a strategic expansion of its pipeline beyond the initial focus on SCLC and LCNEC, leveraging its antibody engineering capabilities to address a wider range of cancers.